AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

nference® Launches First-In-Class Single Cell RNA-Sequencing Resource to Arm Researchers Fighting COVID-19 Pandemic

March 30, 2020 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 30, 2020--

n f erence today announced the launch of a first-in-class software resource that synthesizes disparate Single Cell RNA-sequencing (scRNA-seq) data sets to combat the COVID-19 public health crisis. The resource is equipped with the n f erX augmented intelligence technology that teaches machines to comprehend over 100 million unstructured biomedical documents and triangulate these emergent insights from scientific literature with deep biological signals at single cell resolution.

ADVERTISEMENT

By enabling researchers to study intricate molecular patterns and investigate the heterogeneity of healthy and pathologic tissues alike, the resource will help scientists to rapidly generate and pressure-test new hypotheses. The resource is envisioned to help researchers respond to the coronavirus outbreak, including decoding molecular signatures of viral infection, human-to-human transmission, and increased mortality risk from underlying health conditions or medication regimen. The n f erence Single Cell resource is free to all scientists in the academic community, including physicians and practitioners in academic medical centers.

“Single cell technology is a powerful lens for interrogating molecules that are linked to diseases. However, very few labs have the expert know-how needed to assimilate this data. Furthermore, realizing the full potential of single cell sequencing requires the derivation of reliable insights from the exponentially growing biomedical literature,” said Venky Soundararajan, Ph.D., Co-founder and Chief Scientific Officer of n f erence. “Our mission is to make the world’s biomedical knowledge computable, and with that comes the social responsibility to equip physicians and scientists with the tools needed to help mitigate the scourge of the COVID-19 pandemic.”

n f erence partnered with Janssen, through a broad data science effort that spans across therapeutic areas and functions. The Single Cell resource was developed by n f erence in-part to support Janssen’s discovery of novel therapeutic targets, including cancer sub-types with high unmet clinical need. The two companies also collaborated on a scientific paper published today by bioRxiv for rapid dissemination. The paper serves as a primer to instruct researchers on how to use the n f erence Single Cell resource.

ADVERTISEMENT

The launch of the Single Cell resource by nference for academics worldwide comes following a call to action from the White House to the nation’s Artificial Intelligence (AI) experts to develop new natural language processing technologies that can be used to answer high-priority scientific questions related to the COVID-19 pandemic. n f erence also recently joined the COVID-19 Healthcare Coalition, coordinated by MITRE and first convened by the leaders of Mayo Clinic, Leavitt Partners and several Massachusetts Institute of Technology faculty leaders to form a powerful private sector collaborative that accelerates the development of secure, ethical, innovative, and open source solutions to address the COVID-19 public health crisis. In the spirit of this collaboration, the n f erence Single Cell resource is being made free to all scientists in the academic community, including physicians and practitioners in academic medical centers who are at the frontlines of fighting COVID-19 globally.

“We are pleased to have nference as a collaborator in the COVID-19 Health Coalition and this work illustrates the importance of using natural language processing and machine learning to turn unstructured data into actionable wisdom,” said John Halamka, M.D., President of the Mayo Clinic Platform.

Earlier this year, nference announced a strategic partnership with Mayo Clinic as its first Clinical Data Analytics Platform partner to accelerate drug discovery and development across the biopharmaceutical ecosystem to create cures for patients.

About nferX®

The nferX software platform synthesizes the world’s rapidly growing unstructured, semi-structured and structured biomedical knowledge bases using state-of-the-art neural networks. This platform is being rapidly adopted as the engine-of-choice to power drug discovery, clinical research, clinical trial operations, and lifecycle management applications across the biopharmaceutical continuum.

About n f erence®

Powered by Augmented Intelligence, nference synthesizes the world’s exponentially growing biomedical knowledge to solve the most urgent healthcare problems of our time. nference uses state-of-the-art machine learning to identify patterns and extract insights from public and proprietary scientific, clinical, regulatory and commercial data sets. The technology platform enables understandings to answer queries from a broad range of fields in the life sciences ecosystem, including R&D, commercial strategies and operations. nference enables users to bridge silos of diverse information that exist across disparate bodies in unstructured, semi-structured and structured forms across healthcare organizations. nference is supported by Matrix Partners, Matrix Capital Management, Mayo Clinic Ventures and NTT Venture Capital. For more information, visit nference.ai.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200330005606/en/

CONTACT: For nference:

Rebecca Peterson

rebecca@nference.net

617-678-5711

For Media:

Amanda Houlihan

MacDougall

ahoulihan@macbiocom.com

781-235-3060

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: SCIENCE STEM CELLS BIOTECHNOLOGY RESEARCH HEALTH MEDICAL DEVICES INFECTIOUS DISEASES CLINICAL TRIALS

SOURCE: nference

Copyright Business Wire 2020.

PUB: 03/30/2020 01:08 PM/DISC: 03/30/2020 01:08 PM

http://www.businesswire.com/news/home/20200330005606/en

ADVERTISEMENT